Efficacy of Oral Famotidine and 2 Omeprazole Formulations for the Control of Intragastric pH in Dogs

Tolbert, M Katherine; Bissett, Sally A.; King, AJ; Davidson, Gigi; Papich, Mark G.; Peters, Erin E.; Degernes, Laurel A.

doi:10.1111/j.1939-1676.2010.0651.x

Cited by 92 publications

(145 citation statements)

References 18 publications

(37 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…This result was enough to meet the therapeutic criteria previously described for humans. Previous study to evaluate efficacy of oral omeprazole reported that the MPT with pH ≥4 was 52 ± 17% and 44 ± 18% after treatment with an omeprazole tablet (1.5–2.6 mg/kg q24 hours) and a reformulated omeprazole paste (1.5–2.6 mg/kg q24 hours), respectively 1. The AUC of esomeprazole in people has been reported to be higher than that of omeprazole of the same dose 3.…”

Section: Discussionmentioning

confidence: 99%

“…The duration for which the gastric pH is above 4 has been shown to have a direct relationship to the healing rate in GERD patients, and maintaining the intragastric pH above 4 for at least 16–18 hours is an important therapeutic target for treating these diseases 19, 20. In veterinary medicine, however, no specific standards exist for the duration of drug use or target intragastric pH levels; therefore, MPT for which the pH was ≥3 or ≥4 were considered for dogs as previously reported 1, 11, 21…”

Section: Discussionmentioning

confidence: 99%

“…The Bravo capsules were orally inserted with a delivery system (80 cm in length, with a diameter of 6 Fr.). Under gastroscopic guidance, the capsules were attached to the gastric fundic mucosa as previously described 1, 16. A data receiver was attached to the cage, which remained within 1 m of each dog.…”

Section: Methodsmentioning

confidence: 99%

“…Measuring intragastric pH has been widely accepted as a valid method for comparing and evaluating the efficacy of acid suppressants; however, the correlation between increased intragastric pH and outcome of acid‐related disorders has not been studied enough 1, 5, 6, 8, 9, 10, 11, 12. The aspiration of gastric juices, the placement of a pH electrode through a gastric fistula, and the placement of an pH catheter have been used as methods for measuring gastric pH 7, 8.…”

mentioning

confidence: 99%

“…The aspiration of gastric juices, the placement of a pH electrode through a gastric fistula, and the placement of an pH catheter have been used as methods for measuring gastric pH 7, 8. Previous studies have reported that the aspiration is a relatively invasive technique that may alter gastric physiology, whereas catheterization poses risks of catheter migration and substantial discomfort 1, 13. The Bravo ® pH monitoring system is a wireless radiotelemetric device used for prolonged monitoring of intraesophageal or intragastric pH that is minimally invasive and can avoid the discomforts associated with the previously mentioned methods 14…”

mentioning

confidence: 99%

See 4 more Smart Citations

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Hwang

Jeong

Song

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundEsomeprazole is an S‐enantiomer of omeprazole that has favorable pharmacokinetics and efficacious acid suppressant properties in humans. However, the pharmacokinetics and effects on intragastric pH of esomeprazole in dogs have not been reported.ObjectiveTo determine the pharmacokinetics of esomeprazole administered via various routes (PK study) and to investigate the effect of esomeprazole on intragastric pH with a Bravo pH monitoring system (PD study).AnimalsSeven adult male Beagle dogs and 5 adult male Beagle dogs were used for PK and PD study, respectively.MethodsBoth studies used an open, randomized, and crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC), and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC, and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs.ResultsThe bioavailability of esomeprazole administered as PO enteric‐coated granules and as SC injections was 71.4 and 106%, respectively. The half‐life was approximately 1 hour. Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for IV group, 75.8 ± 16.4% and 62.7 ± 17.7% for SC group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05).ConclusionThe PK parameters for PO and SC esomeprazole administration were favorable, and esomeprazole significantly increased intragastric pH after IV, PO, and SC administration. IV and SC administration of esomeprazole might be useful when PO administration is not possible. No significant adverse effects were observed.

show abstract

Section: Discussionmentioning

confidence: 99%